Imaging the dopaminergic system in suspected parkinsonism, drug induced movement disorders, and lewy body dementia

Nuclear Medicine Communications

Volumn 26, Issue 2, 2005, Pages 87-96

  Kemp, Paul M ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

FP CIT; Lewy Body dementia; Parkinson's disease; SPECT

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; ALTROPANE; ALTROPANE C 11; DOPAMINE; DOPAMINE F 18; EPIDEPRIDE; EPIDEPRIDE I 123; FLUORODEOXYGLUCOSE F 18; IODINE DERIVATIVE; IODOSPIPERONE I 123; IOFLUPANE I 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE I 123; N FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA 4 IODOPHENYLTROPANE I 123; NOMIFENSINE; NOMIFENSINE C 11; RACLOPRIDE; RACLOPRIDE C 11; SPIPERONE; SPIPERONE C 11; TECHNETIUM 99M; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

DEMENTIA; DOPAMINERGIC SYSTEM; DRUG INDUCED DISEASE; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; CLINICAL TRIALS; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEWY BODY DISEASE; PARKINSON DISEASE; PHYSICIAN'S PRACTICE PATTERNS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2;

EID: 13944262205     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200502000-00002     Document Type: Article

References (79)

1. Tanner CM, Hubble JB, Chan P. Epidemiology and genetics of Parkinson's disease. In: Watts RL, Koller WC (editors): Movement Disorders. New York: McGraw-Hill; 1997, pp. 137-152.
2. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28:99-102.
3. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinico-pathologic study? Neurology 1992; 42:1142-1146.
4. MacMahon DG, Thomas S, Campbell S. Validation of the pathways paradigm for the management of Parkinson's disease [Abstract]. In: XIII International Congress of Parkinson's Disease. Parkinsonism and Related Disorders 1999; 5:S53.
5. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of Parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125:861-870.
6. 18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab 1993; 13:43-56.
7. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntingdon. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20:415-455.
8. 123I)β-CIT SPECT. J Neurol 1998; 245:14-20.
9. Dunnett SB, Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 1999; 399(suppl):A32-A39.
10. Brooks DJ. Functional Imaging of Movement Disorders. In: Jankovic J (editor): Parkinson's Disease and Movement Disorders. Baltimore: Williams & Wilkins; 1988, pp. 991-1016.
11. Brooks DJ. The early diagnosis of Parkinson's disease. Ann Neurol 1998; 44(suppl 1):S10-S18.
12. Benamer HTS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of I-123 FP-CIT SPECT imaging; the I-123 FP-CIT Study Group. Mov Disord 2000; 15:503-510.
13. 123I-FP-CIT SPET in differentiating patients with pre-synaptic parkinsonism from other forms of parkinsonism. Eur J Nucl Med 2001; 28:266-272.
14. 123I-Ioflupane (DaTSCAN®) in clinically uncertain Parkinsonian syndromes. Mov Disord 2004; 19:1175-1182.
15. 123I-Ioflupane (DaTSCAN) in clinically uncertain parkinsonian syndromes leads to significant changes in clinical diagnosis. Eur J Nucl Med 2003; 30(suppl 2):S156.
16. 123I-Ioflupane (DaTSCAN) in patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2002; 17(suppl 5):S169.
17. Costa DC, Fontes FRG, Aston PJ, Gacinovic SI. Clinical audit of the impact of DaTSCAN in the management of patients with movement disorders [Abstract]. Nucl Med Commun 2003; 24:445.
18. Benamer HTS, Oertel WH, Patterson J, Hadley DM, Pogarell O, Hoffken H, et al. Prospective study of presynaptic dopaminergic imaging in patients with mild Parkinsonism and tremor disorders; Part I Baseline and 3 month observations. Mov Disord 2003; 18:977-984.
19. Doder M, Rabiner EL, Eturjanski N, Lees AJ, Brooks DJ. Functional imaging of tremor in Parkinson's disease with C11-Way 100635 PET [Abstract]. Neurol 2001; 56:A271-A272.
20. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-CIT-FP/SPECT and fluorine-18-FDOPA-PET. J Nucl Med 1996; 37:1760-1765.
21. 18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab 1993; 13:43-56.
22. 123IFP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiat 1997; 62:133-140.
23. Brooks DJ. Imaging end-points for monitoring neuroprotection in Parkinson's disease. Ann Neurol 2003; 53(suppl 3):S110-S119.
24. Morrish PK. How valid is dopamine transporter imaging as a surrogate market in research trials in Parkinson's disease? Mov Disord 2003; 18:S63-S70.
25. 99mTc TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy controls. J Nucl Med 2000; 41:584-589.
26. 18F-FDOPA in Parkinson's disease patients. J Nucl Med 2003; 44:999-1005.
27. Murrow RW, Schweiger GD, Kepes JJ, Koller WC. Parkinsonism due to basal ganglia lacunar state: clinicopathological correlations. Neurology 1990; 40:897-900.
28. Mark MH, Sage JI, Walters AS, Duvoiisin RC, Miller DC. Binswanger's disease presenting as levodopa-responsive parkinsonism: clinicopathological study of three cases. Mov Disord 1995; 10:450-454.
29. 123I-beta-CIT SPECT distinguishes vascular Parkinsonism from Parkinson's Disease. Mov Disord 2002; 17:518-523.
30. Lincke TJ, Hesse S, Meyer PT, Tietze F, Herrmann W, Sabri O, et al. Value of combined I-123-FP-CIT and I-123-IBZM SPECT imaging for the differentiation of vascular Parkinsonism [Abstract]. J Nucl Med 2003; 44:236P.
31. 99mTc-TRODAT-1. J Nucl Med 2001; 42:408-413.
32. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 2004; 45:1688-1693.
33. Stephen PJ, Williamson J. Drug-induced Parkinsonism in the elderly. Lancet 1984; ii:1082-1083.
34. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiat 1988; 51:850-854.
35. Mutch WJ, Dingwall-Fordyce I, Downie AW, Paterson JG, Roy SK. Parkinson's disease in a Scottish city. BMJ 1986; 292:534-536.
36. Stephen PJ, Williamson J. Drug-induced Parkinsonism in the elderly. Lancet 1984; ii:1082-1083.
37. 18F-dopa PET study. Neurology 1993; 43:552-556.
38. 123I-FP-CIT SPET in differentiating patients with pre-synaptic parkinsonism from other forms of parkinsonism. Eur J Nucl Med 2001; 28:266-272.
39. Parkinson's Disease Society. DaTSCAN-SPECT Diagnostic Imaging in the Management of Parkinson's Disease. (A consensus report from the Parkinson's Disease Society.) Oxford: Darwin Medical Communications Limited; 2002.
40. 18F dopa-PET data. J Neurol Neurosurg Psychiat 1994; 57:278-284.
41. 123I-β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and cortico-basal degeneration. Mov Disord 2000; 15:1158-1167.
42. Brooks DJ. Diagnosis and management of atypical Parkinsonian syndromes. J Neurol Neurosurg Psychiat 2002; 72(suppl 1):i10-i16.
43. 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31:184-192.
44. 123I-IBZM-SPECT. J Neurol Neurosurg Psychiat 1994; 57:1047-1056.
45. Hierholzer J, Cordes M, Venz S, Schelosky L, Harisch C, Richter W, et al. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. J Nucl Med 1998; 39:954-960.
46. 123I-IBZM binding compared with long term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998; 13:16-19.
47. Goldstein DS, Holmes C, Cannon RO. Sympathetic cardioneuropathy in dysautonomias. N Eng J Med 1997; 336:696-702.
48. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155:60-67.
49. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Autonom Res 2001; 11:351-355.
50. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155:60-67.
51. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3:93-103.
52. 18F]fluorodeoxyglucose and PET. Mov Disord 1988; 13:268-274.
53. 18F-FDG. Ann Nucl Med 1997; 11:251-257.
54. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss W-D. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiat 2002; 73:517-523.
55. McKeith I, O'Brien J. Dementia with Lewy bodies. Aust NZ J Psychiat 1999; 33:800-808.
56. Cummings JL. Intellectual impairment in Parkinson's disease: Clinical, pathologic and biochemical correlates. J Geriat Psych Neurol 1998; I:24-36.
57. McKeith I, O'Brien J. Dementia with Lewy bodies. Aust NZ J Psychiat 1999; 33:800-808.
58. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurol 2004; 3:19-28.
59. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305:673-678.
60. Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiat 2002; 73:134-140.
61. Ceravolo R, Volterrani D, Gambaccini, G, Rossi C, Logi C, Mancq G, et al. Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease. Neurol Sci 2003; 24:162-163.
62. 18F-fluorodopa PET study of striatal dopaminergic uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000; 55:1575-1576.
63. Costa DC, Walker Z, Walker RW, Fontes FRG. Dementia with Lewy bodies versus Alzheimer's Disease: Role of Dopamine Transporter Imaging. Mov Disord 2003; 18:S34-S38.
64. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, et al. The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity. Neurology 1990; 40:1-8.
65. Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 60:1586-1590.
66. Rinne JO, Laine M, Kaasinen V, Norvasuo-Heila MK, Nagren K, Helenius H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurol 2002; 58:1489-1493.
67. Ischii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 1998; 51:125-130.
68. 123I] MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Int Med 2003; 42:686-690.
69. 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70:781-783.
70. 123I] MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's type and dementia with Lewy bodies. J Neurol Neurosurg Psychiat 2001; 71:583-588.
71. O'Brien JT, Colloby S, Fenwick J, Williams D, Firbank M, Burn D, et al. Dopamine transporter loss visualised with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004; 61:919-925.
72. Walker Z, Costa DC, Walker RWH, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporters in dementia with Lewy bodies and Parkinson's disease. Neurology 2004; 62:1568-1572.
73. Walker Z, Costa DC, Janssen AG, Walker RWH, Livingston G, Katona CLE. Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with I-123 iodobenzamide single photon emission tomography. Eur J Nucl Med 1997; 24:609-614.
74. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999; 122:1449-1468.
75. Golbe LI. The genetics of Parkinson's disease: a reconsideration. Neurology 1990; 40(suppl 3):7-16.
76. 18F-DOPA positron emission tomography. In: Stern GM (editor): Parkinson's Disease: Advances in Neurology, Vol 80. Philadelphia: Lippincott Williams & Wilkins; 1999, pp. 227-231.
77. 18F]dopa PET. J Neurol Neurosurg Psychiat 1998; 64:314-319.
78. Brooks DJ. The early diagnosis of Parkinson's disease. Ann Neurol 1998; 44(suppl 1):S10-S18.
79. Dunnett SB, Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 1999; 399(suppl):A32-A39.